Ruggedness of Visible Residue Limits for Cleaning Validation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ruggedness of Visible Residue Limits for Cleaning Validation
The author tests the ruggedness of VRL viewing conditions and defines optimal viewing conditions.


Pharmaceutical Technology
Volume 33, Issue 3, pp. 102-111

Results and discussion


Table II: Comparison of visible-residue limit (VRL) data.
Initial versus later VRL determination. Of the original 59 VRLs established (1), the average VRL in this experiment was 1.6 μg/cm2. Three of the four observers agreed on most residue levels, but one observer differed, which resulted in slightly higher VRLs. Of the original set of VRLs, 78% were <2 μg/cm2, but 14% were >4 μg/cm2 (see Table II and Figure 1).


Figure 1: Visible-residue limit (VRL) distribution. (ALL FIGURES ARE COURTESY OF THE AUTHOR.)
Additional VRL determinations increased the experience level, widened the observer pool, and refined the experimental technique. Instead of a small, dedicated group of observers, 20–30 scientists worked on the development compound to establish VRLs. The most significant difference in subsequent VRL determinations, however, was the standardization of the residue-spot preparations using lower spotted residue levels, which resulted in lower VRLs.


Table III: Current visible-residue limit (VRL) data.
Interestingly, variability among the observers decreased even as the observer pool increased. Three major factors led to greater consistency: the initiation of a VRL training program for observers, equipment cleaners, and inspectors; overall increased experience level of the observers; and a more consistent residue-spot preparation technique. Of the additional VRLs established, the average VRL dropped to 0.9 μg/cm2 and 89% of determinations were <2 μg/cm2. Ninety-six percent of the total determinations were <3 μg/cm2, and only 2% were >4 μg/cm2 (see Table II). A t-test comparison of the original and additional VRL data in Figure 1 showed that the data distributions were not equivalent. The additional VRL data with a lower average were statistically different when compared with the original VRL data, which confirmed the effects of experience and technique refinement. The overall average VRL was ultimately <1.1 μg/cm2 for the 253 VRLs (see Table III) because 63% of the VRLs determined were less than the lowest level tested.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here